NIAID Centralized Sequencing Protocol

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age1-100
SponsorNational Institute of Allergy and Infectious Diseases (NIAID)

About this trial

Background:

Genetic testing called "sequencing" helps researchers look at DNA. Genes are made of DNA and are the instructions for our bodies to function. We all have thousands of genes. DNA variants are differences in genes between two people. We all have lots of variants. Most are harmless and some cause differences like blue or brown eyes. A few variants can cause health problems.

Objective:

To understand the genetics of immune disorders various health conditions, as well as outcomes of clinical genomics and genetic counseling services performed under this protocol.

Eligibility:

Participants in other NIH human subjects research protocols - either at the NIH Clinical Center (CC) or at Children s National Health System (CNHS) - (aged 0-99 years), and, in select cases, their biological relatives

Design:

Researchers will study participant s DNA extracted from blood, saliva, or another tissue sample, including previously collected samples we may have stored at the NIH. Researchers will look at participant s DNA in great detail. We are looking for differences in the DNA sequence or structure between participants and other people.

Participants will receive results that:

* Are important to their health * Have been confirmed in a clinical lab * Suggest that they could be at risk for serious disease that may affect your current or future medical management.

Some genetic information we return to participants may be of uncertain importance.

If genetic test results are unrelated to the participant s NIH evaluations, then we will not typically report:

* Normal variants * Information about progressive, fatal conditions that have no effective treatment * Carrier status (conditions you don t have but could pass on)

The samples and data will be saved for future research.

Personal data will be kept as private as possible.

If future studies need new information, participants may be contacted.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

PARTICIPANT

Proband participants: must be individuals under investigation by another NIH protocol on which they are co-enrolled, or are referred from the GDMCC protocol "Defining the Genetic Etiology of Suppurative Lung Disease in Children and Adults" (NCT04702243). Probands may have a disease under investigation or be healthy volunteers

Biological relatives: biologically related to a proband participant.

Aged 0-99 years.

Disqualifiers

None

Trial population

Probands and their biological relatives (primarily clinical), recruited from NIAID protocols (both at the NIH and CNHS).

Trial design

Design model

Family-based

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

20,000 Participants
are grouped into 3 trial groups
Group A: Biological relatives
Group B: Healthy volunteers
Group C: Probands

Trial outcomes

Primary outcomes

1

Identifying novel genetic defects associated with immune disorders

Identifying novel genetic defects associated with immune disorders

Time frame
Upon analysis of genomic data
2

Identifying novel clinical phenotypes associated with established genetic defects

Identifying novel clinical phenotypes associated with established genetic defects

Time frame
Upon analysis of genomic data
3

Identifying established genetic disorders of the immune system

Identifying established genetic disorders of the immune system, as well as known genetic disorders outside of the immune system in some cases

Time frame
Upon analysis of genomic data

Secondary outcomes

1

Evidence base for how to improve clinical genomic services on this protocol and related programs.

Studies of the processes and outcomes of the clinical genomics and genetic counseling services performed under this protocol. These studies will use surveys, interviews, and other social and behavioral research methods to collect data from study participants about their perceptions, experiences, and attitudes related to their condition and participation in this protocol. The goal of these additional studies will be to improve the services provided under protocol 17-I-0122 and to generate an evidence base for other investigators conducting similar studies.

Time frame
5.1.1. Enrollment/Baseline Report Comprehension Survey and Semi-Structured Phone Interviews

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

National Institute of Allergy and Infectious Diseases (NIAID)

Lead sponsor

National Institute of Mental Health (NIMH)

Collaborator